As medicines access evolves and pharmaceutical companies take an increasingly nuanced approach to it, it’s ever-more important to focus on particular aspects of this area and investigate whether firms are operating optimally.
Read more >
To do this Inceptua Medicines Access and patient group, HAEi, in association with PMGroup, will host a free webinar on Thurday 14th December that will cover both the pre-approval access to medicines and the importance of putting patients at the heart of drug development and access.
Pre-approval access - a transformational approach
There are a number of factors at play within the world of medicines access: from industry who need to navigate requests for their pre-approval and unlicensed medicines, to healthcare professionals who are looking for options for their patients and ultimately to the patients and patient advocacy groups who are more empowered than ever and are driving for more timely access to treatments. Today’s healthcare, political and regulatory environments burden have generated a rapid, increasing and significant expansion in the need for access to these medicines. Mark Corbett, Executive Vice President at Inceptua Medicines Access talks about the company’s transformative approach to medicines access, designed to rise to the evolving challenges of the environment, offering unsurpassed understanding and insight into the needs of biopharmaceutical companies and healthcare organisations.
Patients at the heart of drug development and access
If you believe the news every day, patients are becoming more and more involved in drug development and access pathways, but what does this mean in reality